NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Sep 22, 2025Closes
May 8, 2028Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Private institutions of higher education, State governments, Public housing authorities/Indian housing authorities, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal governments (Federally recognized), Special district governments, For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, City or township governments, County governments, Public and State controlled institutions of higher education, Small businesses, Native American tribal organizations (other than Federally recognized tribal governments), Others (see text field entitled "Additional Information on Eligibility" for clarification)
Description
This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC). The overall goal is to move from simply cataloguing genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine